Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)

CAPS Rating: 2 out of 5

The Company develops therapeutic drugs designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses, initially focusing on Alzheimer's disease.

Recs

0
Player Avatar pchop123 (79.46) Submitted: 1/4/2013 11:59:56 AM : Underperform Start Price: $2.35 PRAN Score: +2.43

cash drain issue

Featured Broker Partners


Advertisement